Skip to content

Comparing the effects of gabapentin + different doses of dexamethasone in septoplasty

Comparison of the effects of gabapentin plus different doses of dexamethasone in the management of acute pain after septoplasty

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190325043107N49
Enrollment
75
Registered
2024-08-29
Start date
2024-10-20
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain. Acute pain due to trauma

Interventions

Intervention 1: Intervention group: These patients will take gabapentin (100 mg) orally with 50 ml of water half an hour before the start of anesthesia
Then a dose of 2 mg of dexamethasone (drug volume equal to 1 cc + 1 cc of distilled water in a 2 cc syringe) will be injected intravenously ten minutes before the start of anesthesia. Intervention 2:
Then a dose of 4 mg of dexamethasone (drug volume equal to 2 cc in a 2 cc syringe) will be injected intravenously ten minutes before the start of anesthesia. Intervention 3: Control group: These patie
Then a dose of 2 ml of normal saline serum will be injected intravenously ten minutes before the start of anesthesia.

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with American Society of Anesthesiologists (ASA) Class II and I Candidate for septoplasty surgery

Exclusion criteria

Exclusion criteria: Patients with severe mental disorders, history of epilepsy or seizures Body mass index above 40 kg/m2 Patients with medical conditions (high blood pressure, diabetes, kidney or liver failure)

Design outcomes

Primary

MeasureTime frame
Acute pain. Timepoint: After surgery for 24 hours and once every hour. Method of measurement: Visual analog scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Khanbabayi Gol

Tabriz University of Medical Sciences

Khanbabayimehdi69@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026